These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
93 related items for PubMed ID: 2118853
1. A randomized dose-ranging study of rt-PA in acute myocardial infarction. Effects on coronary patency and fibrinolytic parameters. Koster RW, van Stralen R, McNeill AJ, Adgey AA, Fox KA, Dymond D, Sponzilli C, Jewitt D, Bucknall C, Kluft C. Eur Heart J; 1990 Aug; 11(8):730-9. PubMed ID: 2118853 [Abstract] [Full Text] [Related]
3. Effect of reteplase on hemostasis variables: analysis of fibrin specificity, relation to bleeding complications and coronary patency. Meierhenrich R, Carlsson J, Seifried E, Pfarr E, Smolarz A, Neuhaus KL, Tebbe U. Int J Cardiol; 1998 Jun 01; 65(1):57-63. PubMed ID: 9699932 [Abstract] [Full Text] [Related]
5. Influence of the rt-PA dose (1 mg/kg versus 1.5 mg/kg) and duration of administration on the patency of infarct-related coronary arteries in 81 patients. Gibelin P, Tiger F, Moles V, Bossan S, Blanc P, Baudouy M, Morand P. Cardiovasc Drugs Ther; 1992 Aug 01; 6(4):373-7. PubMed ID: 1520647 [Abstract] [Full Text] [Related]
7. Thrombolysis in Myocardial Infarction (TIMI) Trial--phase I: hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase. Rao AK, Pratt C, Berke A, Jaffe A, Ockene I, Schreiber TL, Bell WR, Knatterud G, Robertson TL, Terrin ML. J Am Coll Cardiol; 1988 Jan 01; 11(1):1-11. PubMed ID: 3121710 [Abstract] [Full Text] [Related]
8. Dose-related efficacy and bleeding complications of double-chain tissue plasminogen activator in acute myocardial infarction. The Wellcome Tissue Plasminogen Activator Study Group. Turi ZG, Goldberg S, LittleJohn JK, Vander Ark C, Shadoff N, Karlsberg R, Williams J, Butman S, Stadius ML, Wise K. Am J Cardiol; 1993 May 01; 71(12):1009-14. PubMed ID: 8475860 [Abstract] [Full Text] [Related]
9. Accelerated plasminogen activator dose regimens for coronary thrombolysis. The TAMI-7 Study Group. Wall TC, Califf RM, George BS, Ellis SG, Samaha JK, Kereiakes DJ, Worley SJ, Sigmon K, Topol EJ. J Am Coll Cardiol; 1992 Mar 01; 19(3):482-9. PubMed ID: 1537998 [Abstract] [Full Text] [Related]
12. Preliminary experience with intravenous P2Y12 platelet receptor inhibition as an adjunct to reduced-dose alteplase during acute myocardial infarction: results of the Safety, Tolerability and Effect on Patency in Acute Myocardial Infarction (STEP-AMI) angiographic trial. Greenbaum AB, Ohman EM, Gibson CM, Borzak S, Stebbins AL, Lu M, Le May MR, Stankowski JE, Emanuelsson H, Weaver WD. Am Heart J; 2007 Oct 01; 154(4):702-9. PubMed ID: 17892995 [Abstract] [Full Text] [Related]
13. Effectiveness and safety of a single intravenous bolus injection of tissue-type plasminogen activator in acute myocardial infarction. Bolus Dose-Escalation Study of Tissue-Type Plasminogen Activator (BEST) Investigators. Hackett D, Andreotti F, Haider AW, Brunelli C, Shahi M, Fussell A, Buller N, Foale R, Lipkin D, Caponnetto S. Am J Cardiol; 1992 Jun 01; 69(17):1393-8. PubMed ID: 1590225 [Abstract] [Full Text] [Related]
16. Effect of heparin on coronary arterial patency after thrombolysis with tissue plasminogen activator in acute myocardial infarction. Bleich SD, Nichols TC, Schumacher RR, Cooke DH, Tate DA, Teichman SL. Am J Cardiol; 1990 Dec 15; 66(20):1412-7. PubMed ID: 2123602 [Abstract] [Full Text] [Related]